Jellyfish from Fisheries By-Catches as a Sustainable Source of High-Value Compounds with Biotechnological Applications.

The world's population growth and consequent increased demand for food, energy and materials together with the decrease of some natural resources have highlighted the compelling need to use sustainably existing resources and find alternative sources to satisfy the needs of growing and longer-aging populations. In this review, we explore the potential use of a specific fisheries by-catch, jellyfish, as a sustainable source of high-value compounds. Jellyfish are often caught up with fish into fishing gear and nets, then sorted and discarded. Conversely, we suggest that this by-catch may be used to obtain food, nutraceutical products, collagen, toxins and fluorescent compounds to be used for biomedical applications and mucus for biomaterials. These applications are based on studies which indicate the feasibility of using jellyfish for biotechnology. Because jellyfish exhibit seasonal fluctuations in abundance, jellyfish by-catches likely follow the same pattern. Therefore, this resource may not be constantly available throughout the year, so the exploitation of the variable abundances needs to be optimized. Despite the lack of data about jellyfish by-catches, the high value of their compounds and their wide range of applications suggest that jellyfish by-catches are a resource which is discarded at present, but needs to be re-evaluated for exploitation within the context of a circular economy in the era of zero waste.

Berberine Derivatives Suppress Cellular Proliferation and Tumorigenesis In Vitro in Human Non-Small-Cell Lung Cancer Cells.

Lung cancer is the leading cause of death in the world, and the most common type of lung cancer is non-small-cell lung cancer (NSCLC), accounting for 85% of lung cancer. Patients with NSCLC, when detected, are mostly in a metastatic stage, and over half of patients diagnosed with NSCLC die within one year after diagnosis; the 5-year survival rate is 24%. However, in patients with metastatic NSCLC, the 5-year survival rate is 6%. Therefore, development of a new therapeutic agent or strategy is urgent for NSCLCs. Berberine has been illustrated to be a therapeutic agent of NSCLC. In the present study, we synthesized six derivatives of berberine, and the anti-NSCLC activity of these agents was examined. Some of them exert increasing proliferation inhibition comparing with berberine. Further studies demonstrated that two of the most effective agents, 9-O-decylberberrubine bromide (B6) and 9-O-dodecylberberrubine bromide (B7), performed cell cycle regulation, in-vitro tumorigenesis inhibition and autophagic flux blocking, but not induction of cellular apoptosis in NSCLC cells. Moreover, B6 and B7 were determined to be green fluorescent and could be penetrated and localized in cellular mitochondria. Herein, B6 and B7, the berberine derivatives we synthesized, revealed better anti-NSCLC activity with berberine and may be used as therapeutic candidates for the treatment of NSCLCs.